{"id":"W2904245464","doi":"10.1093/annonc/mdy487.018","title":"New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ELISPOT; Immune system; Immunogenicity; Survivin; Oncology; T cell; Peripheral blood mononuclear cell; Clinical endpoint; Ovarian cancer; Clinical trial; Internal medicine; Immunology; Cancer; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001978537,0.000899851,0.001798027,0.0002971094,0.0003333849,0.001284833,0.0005094623,0.0008917974,0.006883644],"category_scores_gemma":[0.002127199,0.0002686977,0.001283956,0.0004714707,0.0005702475,0.0007086959,0.0003139802,0.002057502,0.0009490263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006341832,"about_ca_system_score_gemma":0.000839216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006865587,"about_ca_topic_score_gemma":0.002648007,"domain_scores_codex":[0.9992887,0.0004017868,0.00004843288,0.0000825167,0.00009930517,0.00007912445],"domain_scores_gemma":[0.9985471,0.0004927209,0.000343969,0.000133039,0.0001087028,0.0003743814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8739261,0.004480558,0.008937347,0.002663783,0.002908907,0.0002773657,0.0001531566,0.002146429,0.008719671,0.000587373,0.01788293,0.07731626],"study_design_scores_gemma":[0.804322,0.1205328,0.03591573,0.00032424,0.003335093,0.000707566,0.0001422396,0.001123849,0.003269338,0.0009298695,0.0293186,0.00007874593],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9363483,0.01951484,0.0008527218,0.002814373,0.0005468517,0.001849772,0.02053092,0.0001797995,0.01736242],"genre_scores_gemma":[0.9364429,0.008050218,0.001507976,0.003271548,0.0005754439,0.002830929,0.03723513,0.00009863931,0.009987265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006883644,"threshold_uncertainty_score":0.02302814,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1126606931848109,"score_gpt":0.4161583538523176,"score_spread":0.3034976606675067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}